Experiments in RIP1-Tag2 mice have shown that the expression of semaphorin 3A (SEMA3A) is progressively lost during tumor progression and that the inhibition of SEMA3A during the angiogenic switch may enhance tumor formation. The gene discussed is SEMA3A; the disease is neoplasm.